報價延遲最少15分鐘:2025/12/28 08:39 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.37 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.21/-0.31
|
|
企業價值
169.20M
|
| 資產負債 |
|
每股賬面淨值
-0.32
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
1.88M
|
|
每股收益
0.04
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. |
